Analysis of Prognostic Factor in 52 Castration-Resistant Prostate Cancer Treated with Docetaxel

HANDLE Web Site Open Access

Bibliographic Information

Other Title
  • 去勢抵抗性前立腺癌に対しドセタキセルを使用した52例の予後因子の検討
  • キョセイ テイコウセイ ゼンリツセンガン ニ タイシ ドセタキセル オ シヨウ シタ 52レイ ノ ヨゴ インシ ノ ケントウ

Search this article

Abstract

The prognostic factor was retrospectively analyzed in 52 castration-resistant prostate cancer treated with docetaxel (DTX) in our institutions from April, 2006 to August, 2009. The treatment outcomes were decided with prostate specific antigen (PSA) progression-free survival and overall survival. These were calculated by Kaplan-Meier methods and tested with Log-ranktest. Median PSA progression-free survival was 8.8 months and median overall survival was 24.1 months. Prognostic factors on PSA progression were PSA value before DTX treatment and rate of PSA decrement after DTX treatment. Prognostic factors on overall survival were Gleason score (GS), PSA value before DTX treatment, rate of PSA decrement after DTX treatment and positive of bone metastasis in Log-ranktest. Odds ratio of PSA ≧20 ng/ml before DTX treatment was 2.99 and PSA decreasing rate ＜30% was 3.65. These were statistically significant (p ＜0.001) riskfactors in the overall survival.

Journal

  • Hinyokika Kiyo

    Hinyokika Kiyo 58 (1), 7-11, 2012-01

    泌尿器科紀要刊行会

Keywords

Details 詳細情報について

Report a problem

Back to top